1. Home
  2. Companies
  3. MAP
  4. Material Events

Microba Life Sciences (ASX:MAP) — Material Events

ASX:MAP · 12 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 10 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Microba Surges 145% in Test Volumes, Eyes FY26 Break-EvenMedium
Microba reports 145% test volume growth, on track for FY26 break-even with $14.5M capital raise
28 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
Microba Reports 92% Growth in Core Testing Revenue and $7m Cost Savings TargetMedium
Microba reports 92% core testing revenue growth in FY26, new product launch on track, and $7m cost savings target
16 July 2026 ·Quarterly Activities Report and Appendix 4C ·85
Microba Accelerates Growth with New Features and Eyes US Market BreakthroughMedium
Microba reports strong Q1 FY26 growth, new product features, and upcoming therapeutic deal catalysts
28 Oct 2025 ·Quarterly Investor Presentation ·85
Microba Raises $5 Million to Accelerate Diagnostics Growth and Target Break-Even by 2027High
Microba announces A$5 million equity raise to fund path to cashflow break-even by 2027 amid strong diagnostics growth and therapeutics partnering
12 June 2026 ·Equity Raising ·85
Microba Doubles Core Testing Revenue as UK and Clinic Contracts Drive GrowthMedium
Microba Q3 FY26 core testing revenue doubles; new clinic contracts and UK growth drive momentum
30 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·85
Microba Accelerates Core Test Growth with 90% Volume Surge and $2.1M RevenueMedium
Microba reports 90% core test volume growth, $2.1M core revenue, cost savings, and strong clinical adoption
29 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·85
Microba Accelerates Growth, Eyes Break-Even with $15.7m Revenue in Q2 FY26Medium
Microba reports strong Q2 FY26 growth, targets regional break-even, advances therapeutics pipeline
29 Jan 2026 ·Quarterly Investor Presentation ·85
Microba Secures $5.41 Million to Boost Diagnostics Expansion and New Product LaunchMedium
Microba completes $5.41 million capital raising via Placement and Share Purchase Plan
28 July 2026 ·Capital Raising ·75
Microba Reports FY26 Results with Revenue Down 5.8%, Loss Up 38.7%, Core Testing Revenue Up 92%, and Targets Cash Flow Break-Even in 2027Medium
Microba reports FY26 results with revenue down 5.8%, loss up 38.7%, core testing revenue up 92%, and targets cash flow break-even in 2027
31 Aug 2026 ·Annual Report and Financial Results ·75
Microba Life Sciences Seeks $6 Million Capital Boost with SPP and Placement Pending Shareholder NodMedium
Microba Life Sciences launches $6 million capital raise via SPP and Placement with shareholder approval pending
19 June 2026 ·Prospectus ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.